Risk prediction for gastric retention during sedated gastroscopy
Official title: Development and Validation of a Risk Prediction Model for Gastric Retention in Patients Undergoing Sedated Gastroscopy: a Multicentre Prospective Cohort Study
Run by Zhejiang University · NCT07104214 · Data updated 2026-11-12
This study will test a simple grading system and prediction model to see if clinicians can identify which adults are likely to have significant stomach contents before sedated gastroscopy.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 5000 (estimated) |
| Sponsor | Zhejiang University Academic / other |
| Locations | 3 sites (Hangzhou, Zhejiang and 2 other locations) |
| Status | Recruiting |
| Started | August 3, 2025 |
| Main results expected | May 31, 2026 |
| Study ends | May 31, 2026 |
| Registry record updated | March 11, 2026 |
| Trial ID | NCT07104214 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older who are scheduled for elective sedated gastroscopy or sedated gastro-colonoscopy and can provide informed consent are the ideal candidates.
✕Probably not a fit
Patients undergoing emergency endoscopy, those with acute upper GI bleeding, pregnant or lactating people, and children are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective observational study will establish and validate a standardized gastric residual volume (GRV) grading system during elective sedated upper endoscopy. Investigators will record endoscopic findings of retained gastric contents and collect demographic, comorbidity, and medication history data. Those data will be used to build and validate a risk prediction model for gastric retention. The aim is a simplified endoscopy-based tool to help guide fasting and anesthesia planning.
Why it matters
Potential benefit: If successful, the tool could help clinicians identify patients at higher risk of gastric retention so they can tailor fasting instructions and anesthesia plans to reduce aspiration risk.
How similar studies have gone: Related approaches such as gastric ultrasound have shown promise in estimating gastric volume, but a standardized endoscopy-based GRV grading and prediction model is relatively novel and not yet widely validated.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥18 years. * Patients scheduled for elective sedated gastroscopy or sedated gastro-colonoscopy. * Participant provides informed consent. Exclusion Criteria: * Acute upper gastrointestinal bleeding (active hematemesis, melena, or confirmed UGIB within 24h). * Emergency endoscopic procedures * Known pregnancy or lactation * Subjects deemed ineligible by investigators
Where it's running
-
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China Recruiting -
The Second Affiliated Hospital of Jiaxing University
Jiaxing, Zhejiang, China Recruiting -
The Fifth Affiliated Hospital of Wenzhou Medical University
Lishui, Zhejiang, China Not yet recruiting
Study contacts
- Study coordinator: Diansan Su, Chief Physician
- Email: diansansu@yahoo.com
- Phone: +8618616514088
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
PF-08098488 in adults with advanced solid tumors
This study tests PF-08098488 in adults whose cancer has progressed or returned after prior treatment.
-
Modular Robot-Assisted Esophagectomy vs. Conventional Minimally Invasive Esophagectomy for Esophageal Cancer
This trial tests whether modular robotic-assisted esophagectomy using the Carina platform works better than conventional 3D thoracoscopic esophagectomy for people with resectable esophageal cancer.
-
Gastric-focused ultrasound to see if it changes stomach activity and symptoms
This study tests whether noninvasive stomach-focused ultrasound can alter post-meal stomach electrical activity and symptoms in adults with gastroparesis or delayed gastric emptying, using a sham control in a crossover design.
-
MGC030 in adults with advanced solid tumors
This trial tests MGC030 in adults with advanced urothelial, gastric/GEJ, esophageal, colorectal, gastric, pancreatic, or GEJ cancers to see if it is safe and whether it can shrink tumors or stop growth.
-
Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer
This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.
-
TS-104: a first-in-human, dose-escalation study for advanced solid tumors
This study tests TS-104, a peptide-drug conjugate, as a single therapy in adults with advanced solid tumors like NSCLC, HNSCC, esophageal, gastric, ovarian, or endometrial cancer to see if it is safe and tolerable and whether it shows any benefit.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.